A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase 1, Open-Label Study of ABSK121-NX to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05627063
• Other study ID #: ABSK121-NX-101
• Status: Recruiting
• Phase: Phase 1
• Start date: June 26, 2023
• Est. completion date: June 30, 2025

Study information

• Verified date: August 2023
• Source: Abbisko Therapeutics Co, Ltd
• Contact: May Litt
• Phone: +1 5033091243
• Email: may.litt[@]abbisko.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK121-NX administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK121-NX at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

Description:

Escalation Part:

Dose escalation of oral ABSK121-NX will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. During the dose escalation part of the study, patients will receive a single dose of ABSK121 on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) beginning at C1D1.

The dose escalation will start at 3 mg QD followed by dose escalation of a total of 8 potential dose levels. Once RDE is determined, an RDE-confirmation group of up to 24 more patients may be enrolled at the selected dose levels to further evaluate safety and efficacy (up to 12 per dose level/regimen), if approved by the sponsor. In addition, a preliminary food-effect (FE) may be evaluated in Cycle 1 D15 or later in at least 6 patients from the RDE- confirmation part.

After the RDE is determined in the dose escalation part, the dose expansion phase will be conducted.

Expansion Part:

When health authorities outside US require that the safety data in the local population be provided prior to the expansion part, a minimum of 3 local subjects will be enrolled and treated at the selected RDE dose level first in that country/region to evaluate the tolerability of ABSK121-NX. The inclusion and exclusion criteria for escalation part will apply for these subjects. After similar safety and tolerability of ABSK121-NX in patients in the relevant locality have been confirmed by local Investigators and the Sponsor, additional patients will be allowed to enroll in the expansion part.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 169
• Est. completion date: June 30, 2025
• Est. primary completion date: March 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients should understand, sign, and date the written informed consent form prior to screening

2. Male or female age 18 years or older

3. Patients with histologically confirmed locally-advanced or metastatic solid tumors who have progressed on, or are intolerant of standard therapy, or for whom no standard therapy exists, or reject standard therapy

For RDE-confirmation in the escalation part: patients with selected advanced solid tumors, i.e.,

1. Patients must have the following FGFR genetic alterations based on central laboratory tests or existing test reports of tumor tissue and/or blood:

1. Urothelial carcinoma (UC): pre-specified FGFR3 mutations (R248C, S249C, G370C, Y373C) or FGFR2/3 fusions (partner gene is previously described or in frame), or

2. Intrahepatic Cholangiocarcinoma (iCCA): FGFR2 fusions or rearrangements which containing an intact kinase domain as follows:

• FGFR2 fusions: FGFR2 rearrangements with a literature-derived known partner gene regardless of strand or frame, or FGFR2 rearrangements in the same 5' to 3' orientation and in frame with a novel partner gene

• FGFR2 rearrangements: FGFR2 rearrangements with one breakpoint in the hotspot region (intron 17-exon 18) and the other breakpoint in an intergenic region or within another gene, or intragenic duplication of the kinase domain (exon 9-17)

2. Patients must have at least one measurable target lesion according to RECIST 1.1

For the expansion Part:

1) Patients must have the following FGFR genetic alterations based on central laboratory tests or existing test reports of tumor tissue and/or blood:

1. Urothelial carcinoma: pre-specified FGFR3 mutations (R248C, S249C, G370C, Y373C) or FGFR2/3 fusions (partner gene is previously described or in frame)

2. Cholangiocarcinoma: FGFR2 fusions or rearrangements which containing an intact kinase domain as follows:

• FGFR2 fusions: FGFR2 rearrangements with a literature-derived known partner gene regardless of strand or frame, or FGFR2 rearrangements in the same 5' to 3' orientation and in frame with a novel partner gene

• FGFR2 rearrangements: FGFR2 rearrangements with one breakpoint in the hotspot region (intron 17-exon 18) and the other breakpoint in an intergenic region or within another gene, or intragenic duplication of the kinase domain (exon 9-17)

3. Other tumor types: solid tumors harboring FGFR1-4 alterations including activating mutations, fusions or rearrangements and amplifications, e.g., advanced/metastatic gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma harboring the FGFR2 amplifications, or iCCA patients or UC patients with other FGFR alterations not mentioned above, are also allowed

2) Patients must have at least one measurable target lesion according to RECIST 1.1

3) Previous FGFR inhibitors treated and progressed cohort in UC or iCCA patients:

received treatment with FGFR inhibitors and experienced disease progression/recurrence during or after FGFR inhibitors treatment

4. ECOG performance status 0 or 1

5. Life expectancy =3 months

6. Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study drug:

1. Absolute neutrophil count (ANC) =1.5×109/L (without the use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF, M-CSF) within 7 days before testing)

2. Platelet count (PLT) =100×109/L (without transfusion within 14 days before testing)

3. Hemoglobin (Hb) =90 g/L (without transfusion within 7 days before testing)

4. Total bilirubin (TBIL) =1×ULN

5. Aspartate transaminase (AST) and alanine transaminase (ALT) =2.5×ULN

6. Creatinine clearance (Crcl) =60 mL/min based on Cockcroft-Gault formula

7. Electrolyte: magnesium within 0.85 to 1.25 × institutional normal limits, sodium =130 mmol/L, potassium within institutional normal limits 7. For patients participating exploration of food effect:

1. be able to eat a standardized high-fat, high caloric meal within 30 minutes

2. be able to fast for 10 hours

Exclusion Criteria:

1. Known allergy or hypersensitivity to any component of the investigational product

2. RDE-confirmation in Escalation part: Prior treatment with any FGFR inhibitors

3. Expansion part:

1. Previously FGFR-inhibitors naive cohorts in UC or iCCA patients: Prior treatment with any FGFR inhibitors

2. Other solid tumors cohort: Prior treatment with any FGFR inhibitors

4. Has a known additional malignancy that is progressing or has required active treatment.

5. Has persistent phosphate level >ULN during screening (within 14 days prior to the first dose of study treatment) and despite medical management

6. Unable to swallow capsules or tablets or malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction. If any of these conditions exist, the site should discuss with the sponsor to determine patient eligibility

7. Previous anti-cancer therapy, including chemotherapy (chemotherapy with nitrosourea or mitomycin received = 6 weeks prior to initiation of study treatment), radiotherapy, molecular targeted therapy, antibody therapy or other investigational drugs received =4 weeks; endocrine therapy =2 weeks or =5 half-lives (whichever is shorter) prior to initiation of study treatment

8. Major surgery within 4 weeks of the first dose of study drug. Note that all surgical wounds must be healed and free of infection or dehiscence

9. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade =1 severity (CTCAE v5.0) with the exception of alopecia, vitiligo and grade 2 peripheral neurotoxicity

10. Potent inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort). Refer to https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interac tions-table-substrates-inhibitors-and-inducers for a list of drugs

11. Active central nervous system (CNS) metastases including presence of cerebral edema, requirement for systemic steroid treatment, disease progression due to intracranial lesions, leptomeningeal metastasis, and other clinical symptoms related to CNS metastases

12. Impaired cardiac function or clinically significant cardiac disease, including any one of the following:

1. New York Heart Association class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure,

2. Baseline prolongation of the rate-corrected QT interval based on repeated demonstration of QTcF >470 ms (average of screening triplicates) or history of long QT interval corrected (QTc) syndrome (Note: QTc interval corrected by Fridericia's formula),

3. Left ventricular ejection fraction (LVEF) <50% or below the institutional lower limit of normal (whichever is higher)

13. Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for HIV 1/2 antibody

14. Exclusion of hepatitis infection based on the following results and/or criteria:

1. Active hepatitis B infection: positive tests for hepatitis B surface antigen (HBsAg), or antibody to hepatitis B core antigen (anti-HBc). A patient with positive tests for HBsAg or anti-HBc but with HBV-DNA measurements lower than detectable (or per local practice) can be enrolled,

2. Active hepatitis C infection: positive Hepatitis C virus antibody. If positive antibody to hepatitis C Virus (anti-HCV) is detected, Hepatitis C virus RNA by polymerase chain reaction (PCR) is necessary. A patient with positive anti-HCV but with a negative test for HCV RNA can be enrolled

15. Any of the following ophthalmological criteria:

1. Current evidence or previous history of retinal pigment epithelial detachment (RPED) /Central serous retinopathy (CSR)

2. Previous laser treatment or intra-ocular injection for treatment of macular degeneration

3. Current evidence or previous history of dry or wet age-related macular degeneration

4. Current evidence or previous history of retinal vein occlusion (RVO)

5. Current evidence or previous history of retinal degenerative diseases (e.g., hereditary)

6. Diabetic retinopathy with macular edema

7. Current evidence or previous history of any other clinically relevant chorioretinal defect

8. Uncontrolled glaucoma or intraocular pressure > 21 mmHg [after intervention per local standard of care (SOC)]

9. History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids

10. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks prior to first dose) or actively progressing

11. Current evidence or previous history of corneal pathology such as keratopathy, corneal abrasion or ulceration, or current evidence of conjunctivitis

16. Patients with refractory/uncontrolled ascites or pleural effusion

17. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test within 7 days prior to the start of study drug

18. Non-surgically sterilized male or female patients of childbearing potential must agree to use highly effective methods of birth control during the study and for approximately 6 months after the last dose of study drug. A condom is also required to be used by vasectomized men to prevent delivery of the drug via seminal fluid

19. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines (e.g., COVID-19 vaccines, inactivated influenza vaccines)

20. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks

21. Planned major surgery during study treatment

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• ABSK121-NX
In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.

Locations

Country	Name	City	State
China	Fujian Cancer Hospital (Department of Hepatobiliary and Pancreatic Oncology /Phase I Ward)	FuZhou
China	Harbin Medical University Cancer Hospital (Gastroenterology Department 2nd Ward)	Haerbin
China	Zhongshan Hospital of Fudan University (Hepatological Surgery Department)	Shanghai
China	Zhongshan Hospital of Fudan University (Medical Oncology Department)	Shanghai
China	Liaoning Cancer Hospital (Phase I Ward)	Shenyang
China	Yantai Yuhuangding Hospital (Department of Medical Oncology, 1)	Yantai
United States	Gabrail Cancer Center Research	Canton	Ohio
United States	Karmanos Cancer Institute	Detroit	Michigan
United States	Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada

Sponsors (1)

Lead Sponsor	Collaborator
Abbisko Therapeutics Co, Ltd

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of DLT	dose-limiting toxicities (DLTs)	At the end of Cycle 1 (each cycle is 28 days)
Primary	Incidence and severity of adverse events (AEs)	adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)	Through study completion, an average of half year
Secondary	Cmax	maximum observed concentration	Through the study completion, an average of half year
Secondary	Tmax	time to maximum observed concentration	Through the study completion, an average of half year
Secondary	AUC	area under the concentration-time curve	Through the study completion, an average of half year
Secondary	t1/2	half-life	Through the study completion, an average of half year
Secondary	Vz/F	apparent volume of distribution	Through the study completion, an average of half year
Secondary	CL/F	apparent oral clearance	Through the study completion, an average of half year
Secondary	Cmax,ss	maximum observed concentration of steady/state	Through the study completion, an average of half year
Secondary	Cmin,ss	minimum observed concentration of steady/state	Through the study completion, an average of half year
Secondary	AUCtau,ss	area under the concentration-time curve after multiple dose	Through the study completion, an average of half year
Secondary	AR	accumulation ratio	Through the study completion, an average of half year
Secondary	ORR	overall response rate	Through the study completion, an average of half year
Secondary	DoR	duration of response	Through the study completion, an average of half year
Secondary	DCR	disease control rate	Through the study completion, an average of half year
Secondary	PFS	Progression-free survival	Through the study completion, an average of half year
Secondary	OS	overall survival	Through the study completion, an average of half year